Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Joshua Williams

Physician Assistant, Medical St George, UT Physician Assistant

NPI 1093085276 CMS profile 1077592

617 E Riverside Dr, Ste 301, St George, UT 84790

Open in the dashboard

General payments

$4,031

184 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joshua Williams of St George, UT is reported in the CMS Open Payments database as having received $4,031 across 184 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $689 37
2024 General $1,679 75
2023 General $911 57
2022 General $754 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Williams
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Joshua Williams were reported at $689. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Joshua Williams Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $754 $185 $55–$649 $149
2023 $911 $199 $58–$717 $160
2024 $1,679 $206 $62–$740 $164
2025 $689 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Medtronic, Inc. $1,318 52 payments
  2. Boston Scientific Corporation $648 64 payments
  3. Nalu Medical, Inc. $641 7 payments
  4. Pfizer Inc. $381 17 payments
  5. AbbVie, Inc. $238 8 payments
  6. Lundbeck LLC $201 9 payments
  7. SPR Therapeutics, Inc $122 8 payments
  8. Nevro Corp. $114 3 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $80 2 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $70 4 payments
  11. Other $217 10 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,858 177 payments
  2. Travel and Lodging $1,128 6 payments
  3. Education $45 1 payment
Products named General payments · program years 2022–2025
  1. SYNCHROMEDII $814 9 payments
  2. Nalu Neurostimulation System $641 7 payments
  3. INTELLIS ADAPTIVESTIM $456 37 payments
  4. NURTEC ODT $342 16 payments
  5. UBRELVY $203 6 payments
  6. VYEPTI $174 8 payments
  7. QULIPTA $151 4 payments
  8. SPRINT PNS System $122 8 payments
  9. Senza $114 3 payments
  10. General - Therapies $88 8 payments
  11. Other $805 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

1,666

Median for Physician Assistant: 241

Drug cost

$40,083

Median for Physician Assistant: $4,110

Branded share of claims

42.7%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 14 $9,220
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 396 $8,352
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 189 $4,930
Oxycodone Hcl Generic 174 $4,064
Gabapentin Generic 228 $2,596
Fentanyl Generic 31 $2,440
Morphine Sulfate Er Morphine Sulfate Brand 96 $1,935
Lidocaine Generic 17 $1,519
Baclofen Generic 79 $1,301
Pregabalin Generic 84 $672

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 17 billing codes

Paid by Medicare

$129,302

Of which drugs: $12,868

Medicare patients

389

Average age 73

Services billed

3,901

207 women, 182 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 72%
Depression 31%
Diabetes 30%
Chronic kidney disease 26%
Ischemic heart disease 23%
COPD 16%
Heart failure 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 22 55 $43

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NURTEC ODT
  • PFIZER INC. $110
$110 — —
VYEPTI
  • Lundbeck LLC $84
$84 — —
UBRELVY
  • AbbVie, Inc. $32
$32 — —
Qutenza
  • Averitas Pharma Inc. $17
$17 — —
QULIPTA
  • AbbVie, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

184 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record